Palisade Bio said members of management will participate in three healthcare investor conferences in September 2026. The schedule includes investor meetings at the Wells Fargo 2026 Healthcare Conference in Boston from Sept. 8-10; an in-person fireside chat and investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, with the fireside chat set for Sept. 16 from 10:00-10:35 a.m. ET; and an in-person fireside chat and investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, also in New York, with a presentation scheduled for Sept. 16 from 3:00-3:30 p.m. ET in Kennedy II, 4th Floor. Live webcasts and limited-time replays will be available through the Events page in the Investors section of Palisade Bio's website. The clinical-stage biopharmaceutical company is advancing its lead candidate PALI-2108 into Phase 2 trials for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.